Bristol Myers Squibb wraps up $13.1bn acquisition of MyoKardia
Bristol Myers Squibb has wrapped up its previously announced $13.1 billion acquisition of MyoKardia, a California-based clinical-stage biopharma company. Following the closing of the deal, ... Read More
ExeGi Pharma gets FDA orphan drug status for EXE-346 in pouchitis
ExeGi Pharma said that EXE-346 has been granted an orphan drug designation from the US Food and Drug Administration (FDA) for the prevention of disease ... Read More
Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer
Olema Oncology has entered into a clinical trial agreement with Pfizer to evaluate its small molecule OP-1250 in combination with the latter’s palbociclib (IBRANCE) in ... Read More
US medical device company Adagio Medical raises $42.5m in Series E
Adagio Medical, a California-based medical device company focused on developing treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), has raised $42.5 million in a ... Read More
Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA
The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly ... Read More
BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech
Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in ... Read More
Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline
Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash ... Read More
Janssen seeks EMA’s expanded approval for DARZALEX in AL amyloidosis
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency (EMA) seeking the expanded approval ... Read More
Swiss biotech company Memo Therapeutics raises $15.5m in Series B round
Memo Therapeutics has raised CHF14 million ($15.56 million) in a Series B financing round towards the clinical development of potent antibodies for the immunotherapy of ... Read More
Pfizer’s tofacitinib succeeds in phase 3 ankylosing spondylitis trial
Pfizer said that a phase 3 clinical trial of XELJANZ (tofacitinib) in adults with active ankylosing spondylitis (AS) has met its primary endpoint. The late-stage ... Read More